From: Olmsted syndrome: exploration of the immunological phenotype
Subset | Defining surface markers | Patient (%) | Healthy volunteers (%) | Â |
---|---|---|---|---|
 |  |  | Mean (SD) | Median (min-max) |
T cells | CD3+ | 25.0 | 21.7 (10.7) | 20.2 (8.48-41.6) |
CD4 + subsets | Â | Â | Â | Â |
CD4+ T cells | CD4+CD8- | 18.2 | 11.0 (6.03) | 7.79 (3.82-19.9) |
 →Treg | Foxp3+ | 1.91 | 3.67 (2.52) | 2.97 (1.54-9.37) |
 →Th1 | IFNγ+ | 1.22 | 3.18 (1.57) | 3.36 (0.96-5.28) |
 →Th2 | IL-4+ | 2.14 | 5.03 (2.45) | 5.12 (1.90-11.0) |
 →Th17 | IL-17+ | 0.08 | 0.05 (0.04) | 0.03 (0–0.1) |
 →IL-2+ | IL-2+ | 1.69 | 2.25 (1.06) | 2.67 (0.95-4.11) |
 →Tfh | CD45RA-CXCR5+ | 0.59 | 0.14 (0.11) | 0.11 (0.026-0.41) |
 →Naïve | CD45RA+CCR7+ | 61.3 | 44.1 (9.73) | 43.6 (31.0-58.4) |
 →RTE | CD45RA+CCR7+CD31+ | 46.3 | 35.6 (8.77) | 35.7 (22.8-49.7) |
 →TCM | CD45RA-CCR7+ | 14.6 | 12.2 (4.24) | 11.6 (6.36-18.7) |
 →TEM | CD45RA-CCR7- | 15.6 | 32.5 (7.54) | 35.2 (21.0-43.7) |
 →TEMRA | CD45RA+CCR7- | 8.50 | 11.9 (5.55) | 7.78 (6.52-21.2) |
CD8 + subsets | Â | Â | Â | Â |
CD8+ T cells | CD4-CD8+ | 7.75 | 9.51 (4.12) | 8.64 (4.45-17.5) |
 →IFNγ+ | IFNγ+ | 8.1 | 23.3 (9.09) | 19.9 (12.7-40.0) |
 →IL-2+ | IL-2+ | 1.48 | 3.46 (1.74) | 2.82 (1.78-7.17) |
 →Naïve | CD45RA+CCR7+ | 60.9 | 41.2 (13.9) | 37.4 (26.3-62.2) |
 →RTE | CD45RA+CCR7+CD31+ | 59.0 | 38.2 (14.0) | 32.3 (24.0-60.0) |
 →TCM | CD45RA-CCR7+ | 3.08 | 3.11 (1.52) | 2.91 (1.08-6.00) |
 →TEM | CD45RA-CCR7- | 16.0 | 24.1 (7.63) | 22.0 (14.8-41.3) |
 →TEMRA | CD45RA+CCR7- | 20.1 | 31.6 (12.5) | 31.2 (15.3-49.9) |